trending Market Intelligence /marketintelligence/en/news-insights/trending/1tqtcUxBVB3r1_hRCRh7qA2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Qiagen's molecular testing system cleared by US FDA


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


COVID-19 Impact & Recovery: Private Equity

Qiagen's molecular testing system cleared by US FDA

Qiagen NV said the U.S. Food and Drug Administration granted 510(k) clearance to its molecular diagnostic system QIAstat-Dx.

The Netherlands-based company developed QIAstat-Dx syndromic testing system to detect and identify multiple respiratory viral and bacterial pathogens.

Qiagen launched the QIAstat-Dx syndromic testing system together with its multiplex QIAstat-Dx respiratory panel.